The US President Trump signed an executive order on Tuesday, allocating $50 million to promote the application of artificial intelligence in childhood cancer research. This move has attracted widespread attention, especially against the backdrop of increased adoption of artificial intelligence by federal agencies, while simultaneously facing reduced biomedical research funding and the suspension of some research grants.
Michael Kratsios, director of the White House Office of Science and Technology Policy, stated that the order requires the "Cancer Moonshot Task Force" appointed by the president to collaborate with the Office of Science and Technology Policy to fully utilize the Childhood Cancer Data Initiative established during Trump's first term. This investment will double the budget of the data initiative. Kratsios emphasized that researchers will use this data infrastructure to improve clinical trial processes, enhance diagnostic accuracy, optimize treatment plans, find cures, and strengthen cancer prevention strategies through artificial intelligence.
For example, research teams plan to build scalable models to predict children's physical responses to treatments, thereby better anticipating cancer progression and reducing treatment side effects. Dr. Jay Bhattacharya, director of the National Institutes of Health, noted that in the future, artificial intelligence may help researchers find "more effective treatments with fewer side effects."
According to White House officials, this new initiative will integrate existing technologies, but it is not yet clear which specific companies or software are involved. The related research projects will be widely solicited from the public, focusing on using artificial intelligence to combat childhood cancer. In addition, electronic health records and claims data will also be used to support research and clinical trial design.
Key Points:
🌟 President Trump signed an order, investing $50 million in artificial intelligence research for childhood cancer.
🤖 The new initiative will use artificial intelligence to improve clinical trials and enhance the effectiveness of treatment plans.
📉 Despite budget cuts, the White House reaffirmed its full support for biomedical research.
